Award Number: DAMD17-99-1-9125

TITLE: Functional Imaging of Multidrug Resistance in Breast Cancer with PET

PRINCIPAL INVESTIGATOR: Alan Packard, Ph.D.

CONTRACTING ORGANIZATION: Children's Hospital Corporation
Boston, Massachusetts 02115

REPORT DATE: August 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
The objective of this project is the development of a PET radiopharmaceutical for the evaluation of multidrug resistance (mdr) in breast cancer. Multidrug resistance is resistance of a lesion to a specific class of drugs that includes many of the chemotherapeutics that are most effective against breast cancer and is characterized by the increased concentration of P-glycoprotein (Pgp), a 170 kD transmembrane glycoprotein, which reduces the intracellular concentration of these drugs to non-toxic levels. Lipophilic cationic complexes such as $^{99m}$Tc-MIBI are substrates for Pgp and are now being studied for evaluation of mdr function in vivo. We are currently carrying out in vivo and in vitro studies of lipophilic cationic $^{64}$Cu-based PET radiopharmaceuticals as possible PET mdr radiopharmaceuticals. A PET mdr tracer will provide significant advantages over $^{99m}$Tc-MIBI, and the half-life of $^{64}$Cu (12.7 h) is better matched to the apparent biological half-life of the mdr process (~240 min.) than are other PET radionuclides (e.g., $^{11}$C, $T_{1/2}=11$ min). These radiopharmaceuticals may provide information about the mdr status of breast cancer lesions that will allow optimization of treatment protocols, monitoring of the development of acquired resistance, and real-time evaluation of the effectiveness of drugs developed to modulate mdr.
# Table of Contents

Cover .................................................................................................................. 1

SF 298 ................................................................................................................. 2

Table of Contents ............................................................................................... 3

Introduction ........................................................................................................... 4

Body .................................................................................................................... 4

Key Research Accomplishments .................................................................... 6

Reportable Outcomes ....................................................................................... 6

Conclusions ......................................................................................................... 7

References ........................................................................................................... 7

Appendices .......................................................................................................... 8
INTRODUCTION
The objective of this project is the development of a PET (Positron Emission Tomography) radiopharmaceutical for the quantitative functional evaluation of multidrug resistance (mdr) in breast cancer. Multidrug resistance (mdr) is defined as intrinsic or acquired resistance to a specific class of chemotherapeutic drugs that includes many of the most effective chemotherapeutic agents against breast cancer. Multidrug resistance is characterized by overexpression of the MDR1 gene and increased concentration of its product, P-glycoprotein (Pgp), a 170 kD transmembrane glycoprotein, which acts as an efflux pump to reduce the intracellular concentration of these drugs to non-toxic levels. Lipophilic cationic complexes such as $^{99m}$Tc-MIBI are substrates for Pgp and are now being studied for clinical evaluation of mdr. We are currently carrying out in vivo and in vitro studies of lipophilic cationic $^{64}$Cu-based PET radiopharmaceuticals as possible PET mdr radiopharmaceuticals. A PET mdr tracer will provide significant advantages over $^{99m}$Tc-MIBI (e.g., straightforward attenuation corrections, higher spatial resolution, greater sensitivity, and the ability to perform quantitative studies), and the half-life of $^{64}$Cu (12.7 h) is better matched to the apparent biological half-life of the mdr process (~240 min.) than are other PET radionuclides such as $^{11}$C ($T_{1/2}$ = 11 min). Furthermore, $^{11}$C-based radiopharmaceuticals are only available at a limited number of institutions and, because of the short half-life of $^{11}$C, cannot be shipped to other institutions. These radiopharmaceuticals will provide real-time information about the mdr status of breast cancer lesions that may allow optimization of treatment protocols, monitoring of the development of acquired resistance, and evaluation of the effectiveness of drugs developed to modulate mdr.

BODY
The research accomplishments are discussed in terms of each Task outlined in the Revised Statement of Work (6/1/99) relevant to the first 12 months of the Project (6/1/99-7/31/00).

Task 1. Recruitment and training of research technician, Months 1-3
Ms. Erica A. Guice was hired as a research technician October, 1999, after review of approximately 60 applications and interviews with five finalists. Ms. Guice received her B.S. degree in Cell & Molecular Biology from the University of Michigan in May of 1999 during which time she was a research technician in the Department of Neurology. A copy of her CV is appended to this report.

During the first two to three months of Ms. Guice's appointment she underwent required new employee training sessions including Lab Safety Training, Radiation Safety Training, Animal Use Orientation (including Small Animal Use) at both Children's Hospital and Harvard Medical School.

During this time she also worked with the research technician in the laboratory of Dr. Alun Jones at Harvard Medical School, who maintains the multidrug-resistant MES-SA/Dx5 (uterine sarcoma) cell line that was used in previous studies in our laboratory, to learn the techniques required to establish and maintain drug resistant cell lines and the techniques required to measure uptake of the new radiotracers in these cells.

Because of space constraints at Harvard Medical School, it became necessary to establish a separate tissue culture facility in our laboratory. A suitable incubator was obtained on loan from Dr. Jones' laboratory, and much of the other required equipment was already available in our facility. Establishing this facility did, however, increase the time required to produce the target breast cancer cell lines.
Task 2. Establish and validate in vitro assay for multidrug resistant breast cancer, Months 3-12:

a. Establish breast cancer cell lines
b. Establish mdr breast cancer cell lines
c. Validate parental and mdr breast cancer cell lines with $^{99m}$Tc-MIBI
d. Validate parental and mdr breast cancer cell lines with prototype $^{64}$Cu PreH and cyclops complexes

This task is being pursued through two approaches; the rat MAT-B cell line and the human MCF-7 cell line. The MAT-B cell line has the advantage that is native to the Fischer rat – it was developed from a solid mammary adenocarcinoma - and is, therefore, expected to show more physiologically relevant perfusion when in vitro studies are carried out. The human-derived MCF-7 adenocarcinoma cell line is more relevant to the problem of human breast cancer, but in vivo studies must be carried out as xenografts in nude mice with the associated differences between the two species.

The first task was to establish wild-type and multidrug-resistant breast cancer cell lines. This task has been pursued with both the MAT-B and MCF-7 cell lines. The wild-type MAT-B cell line was obtained through our collaboration with Alun Jones, Ph.D., at Harvard Medical School. The mdr MAT-B sub-line was to have been developed in the fall and winter of 1999-2000 in Prof. Jones laboratory using standard procedures, but the associate is this laboratory who was to prepare these cells was on leave from approximately November, 1999, through March, 2000. One of her first objectives when she returned was to begin the process of preparing this resistant sub-line. This task is now expected to be completed this fall (2000). Both in vitro and in vivo studies will begin as soon as the cell line is validated.

Studies with the MCF-7 cell line were pursued in two ways. The first approach was to attempt to develop an mdr MCF-7 cell line in house from parental (non-resistant) MCF-7 cells obtained from ATCC, using the same approach used in Dr. Jones' laboratory on the MAT-B cell line. This approach is based on increasing the concentration of adriamycin in the culture media, starting at $1 \times 10^{-6}$M and then increasing the concentration to $5 \times 10^{-6}$M, $1 \times 10^{-5}$M, $5 \times 10^{-5}$M, etc. We found, however, that this rate of increase in the adriamycin concentration was too great. A significantly lower rate of increase, on the other hand, would require many months before an adequately resistant cell line was obtained. This approach was, therefore, set aside when the cells were at the $1 \times 10^{-6}$M level.

Alternatively, MCF-7 mdr cell lines were obtained from were obtained from Drs. Grace Yeh (NIH) and Robert Gillies at the University of Arizona. In neither case, however, were our first efforts to cultivate these cells successful. In our hands, the Yeh cell lines did not grow in the presence of adriamycin. Based on correspondence with Dr. Yeh, we are developing a new working stock of these cells in the absence of adriamycin. Similarly, the first attempt to grow the resistant MCF-7 cells supplied by the Arizona Cancer Center was unsuccessful, apparently because of a problem with the cell line that was supplied. A second set of samples was recently obtained, and these are now being cultivated in our laboratory.

Because of the problems related to obtaining the resistant MCF-7 cell lines from other investigators, we are also now resuming our effort to develop resistant sub-lines in house. This effort was recently undertaken and will begin with the cells from the highest doxorubicin concentration achieved previously, $1 \times 10^{-5}$ M. In this case the doxorubicin concentration will only be increased by a factor of two every 2-3 doubling times (4-6 days) with sufficient time allowed between increases for the cells to recover. This procedure is based on that used in Dr. Jones laboratory for the MAT-B cell line and is significantly slower than was used when we
initially tried to prepare the resistant sub-lines in house and is consistent with the rate of increase that is being used successfully in the MAT-B cells.

During the period when we have been addressing the problems associated with developing the drug resistant breast cancer cell lines, we have validated the in vitro assay techniques using the (previously established) MES-SA (parental) and MES-SA/Dx5 (resistant) uterine sarcoma cell lines. An abstract describing these results was submitted for presentation at the PacifiChem 2000 meeting. A copy of the abstract is included in the Appendix.

Task 3. Establish and validate in vivo assay for multidrug resistant breast cancer, Months 3-12:
   a. Establish breast cancer cell lines in animal model
   b. Establish mdr breast cancer cell lines in animal model
   c. Validate parental and mdr breast cancer cell lines with 99mTc-MIBI
   d. Validate parental and mdr breast cancer cell lines with prototype 64Cu PreH and cyclops complexes

In vivo testing of the new imaging agents will not be undertaken using a breast cancer model until the multidrug-resistant breast cancer cell lines are well established. Our revised estimate for this is Fall, 2000. Part of this delay is due to the problems that we have encountered in establishing the two mdr breast cancer cell lines and part is also due to the requirement that all new cell lines be extensively tested for rodent pathogens before they are used in animals that will be housed in the Children's Hospital animal facility. The cell lines can not be tested until they are well-established, and the in vivo studies can not be undertaken until the cell lines are tested.

KEY RESEARCH ACCOMPLISHMENTS
- Recruited and trained research technician
- Established tissue culture facility in Children's Hospital Nuclear Medicine Laboratory
- Established human and murine breast cancer cell lines
- Multidrug resistant human and murine breast cancer cell lines are in process
- Validated techniques for in vitro measurement of uptake of new radiopharmaceuticals

REPORTABLE OUTCOMES
Manuscripts, abstracts, and presentations
A copy of the abstract is appended to this report

Cell lines
The MES-SA and MES-SA/Dx5 (human uterine sarcoma) cell lines are established and being used for method validation.
The MAT-B (rat mammary adenocarcinoma) parental cell line is established and the resistant subline will be available in Fall, 2000.
The parental and resistant MCF-7 (human mammary adenocarcinoma) cell lines are being evaluated at this time.
CONCLUSIONS
At this early stage of the project, it is not yet possible to draw any conclusions about the validity of using $^{64}$Cu-based PET radiopharmaceuticals for the quantitative functional evaluation of multidrug resistance in breast cancer. We have, however, after some initial problems, been able to establish the foundation for the in vivo and in vitro evaluation of these new imaging agents in the remaining years of this project. These problems also provided the impetus to expand the range of cell lines that are being used for this evaluation, which will provide a more complete picture of the biological properties of the compounds. During this time we have also acquired a wider variety of $^{64}$Cu complexes to test when the cell lines are available. This expanded chemical diversity will also contribute to the overall goal of obtaining as complete as possible of the interrelationships between the chemical and biological properties of $^{64}$Cu-based PET radiopharmaceuticals for evaluating multidrug resistance in breast cancer.

REFERENCES
N/A
APPENDICES

(Erica Guice CV, PacificChem 2000 Abstract)
Erica Angelique Guice
15 Copley
Roxbury, MA 02119
617-355-7560

guice@al.tch.harvard.edu

Education:
August 1995- May 1999
University of Michigan
Ann Arbor, MI 48109
BS, Cell & Molecular Biology

August 1991- June 1995
Cass Technical High School
2421 Second Ave.
Detroit, MI 48201
Chemical Biological

Work Experience:
October 1999-Present
Children Hospital
Department of Nuclear Medicine
300 Longwood Ave.
454 Enders
Boston, MA 02115

May 1997- May 1999
University of Michigan Hospitals
Department of Neurology
1500 E. Medical Center Drive
5214 Cancer Center and Geriatric Center
Ann Arbor, 48109

Activities:
April 1998-Present
Alpha Chi Sigma Professional Chemical Sciences Fraternity
Alpha Beta Chapter
1319 Cambridge Street
Ann Arbor, MI 48105

April 1997- Present
Gamma Delta Iota Sorority
Omega Chapter
5731 Edge Waters Landing Ct.
Burke, VA 22015

August 1995-May 1997
University of Michigan Marching Band
Revelli Hall
Ann Arbor, MI 48109

Resources available upon request.
Synthesis and Characterization of Carrier-Free $^{64}$Cu Diimidoxime Complexes – Potential PET Radiopharmaceuticals for Evaluating Multidrug Resistance

The aim of this work is to develop $^{64}$Cu-based PET radiopharmaceuticals for the functional evaluation of multidrug resistance in breast cancer and other malignancies. We previously identified the lipophilic cationic copper(II) complexes of the diimidoxime ligands as promising candidates for this application using low specific-activity $^{64}$Cu (2 mCi/mg) and carried out preliminary biological studies that confirm the potential utility of these complexes for this application. We have now developed a rapid synthesis (<5 min.) for use with high specific-activity (HSA) $^{64}$Cu (>105 mCi/mg) that produces these complexes in 90% yield and 90% radiochemical purity and characterized the products by HPLC and ITLC using the "cold" complexes as standards. In vitro stability was tested by equilibration of the $^{64}$Cu-complex with 2.5% BSA/PBS using a Sephadex G-50 column, which revealed no evidence of plasma binding or transchelation of $^{64}$Cu to albumin. Additional in vivo and in vitro studies are currently underway.